Orthopedic implants and instruments maker
) recently revealed that it has obtained 510k clearance from the
U.S. Food and Drug Administration (FDA) for its Flash Pak Evolution
valve. The valve is designed for usage with the company's Flash Pak
SYMMETRY MEDICL (SMA): Free Stock Analysis
STRYKER CORP (SYK): Free Stock Analysis Report
ZIMMER HOLDINGS (ZMH): Free Stock Analysis
To read this article on Zacks.com click here.
The company has applied for a patent for the valve's stainless
steel design, intended for easy usage. This valve will be solely
sold by the company's wholly owned subsidiary Symmetry
Symmetry recently retained its guidance for 2012. The company
continues to expect sales in a band of $410 million and $425
million for the full year.
The earnings per share (on a reported basis) target has been set in
a range of 30 cents to 40 cents for 2012. Adjusted earnings per
share are expected between 55 cents and 65 cents. The forecast
excludes one-time items such as facility closure/severance,
acquisition, impairment, amortization and legal charges, which are
expected to dilute 2012 earnings by roughly 25 cents a share.
Symmetry is the largest OEM provider of implants and related
surgical instruments and cases to orthopedic devices manufacturers.
Its major customers include Johnson & Johnson's DePuy,
The company has created a distinct competitive niche in the
orthopedic devices market with its "Total Solutions Approach." It
is investing in management structure revamp and enhancing customer
collaboration, which should push growth moving forward.
Symmetry in December 2011, completed its $165 million takeover of
the surgical instruments business of Codman. Besides diversifying
its revenue base, the acquisition enables the company to broaden
its global presence.
However, Symmetry still faces price and procedure volume pressure
on the orthopedic front. Also, the company's high spending may
continue to weigh on its bottom line. We are currently Neutral on
the stock, supported by a short-term Zacks #3 Rank (Hold).